Results 191 to 200 of about 159,798 (214)

Signaling Bias as a Framework for Therapeutically Relevant Orthosteric Agonists: The β₂ Adrenergic Receptor Paradigm. [PDF]

Biochemistry
Georgiou K, Kolocouris A.
europepmc   +1 more source

Long-acting muscarinic antagonist and long-acting β₂-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review. [PDF]

Ther Adv Respir Dis
Buhl R, Miravitlles M, Anzueto A, Brunton S.   +3 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell Metabolism, 2022
William C Roell, Corina Loghin, Daniel A Briere   +2 more
exaly  

Agonist antibody discovery: Experimental, computational, and rational engineering approaches

Drug Discovery Today, 2022
Harkamal S Jhajj, Peter M Tessier
exaly  

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Yukiko Onishi, Tetsuya Kubota, Hiroaki Fujiwara   +2 more
exaly  

The promise and challenges of immune agonist antibody development in cancer

Nature Reviews Drug Discovery, 2018
Patrick A Mayes, Mayes Patrick A
exaly  

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell Metabolism, 2017
Juan P Frías, Matthias H Tschop, Christophe Schmitt   +2 more
exaly  

Agonist binding, agonist affinity and agonist efficacy at G protein‐coupled receptors

British Journal of Pharmacology, 2008
Philip G Strange
exaly